Skip to main content

Table 3 MCDA outcomes for drug-indication pairs appraised by AHTAPol between 2007 and 2011 (economic criteria excluded)

From: Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs

No. Drug-indication pair Indication uniqueness Disease rarity Disease severity Adv.tech. Manufacturing technology Therapeutic alternative Sci. evid. clin.eff. Benefits from use of medicine Total number of points
1 Elaprase 2 2 1 2 2 2 1 1 13
2 Fabrazyme 2 2 2 2 2 0 1 1 12
  THRESHOLD 75 %         12 points
3 Nexavar (HCC) 1 2 2 0 2 2 2 0 11
4 Kuvan 0 2 1 1 2 2 1 2 11
5 Nplate 2 1 0 2 2 2 1 1 11
6 Cystadane 2 2 2 0 0 2 0 2 10
7 Yondelis 1 1 2 2 0 2 2 0 10
8 Somavert 2 1 1 2 2 0 1 1 10
9 Tasigna 2 2 2 0 0 2 1 1 10
10 Increlex 2 0 0 2 2 2 1 1 10
11 Glivec – (GIST) 0 2 2 0 1 2 2 0 9
12 Revlimid (MM/S) 1 0 2 1 0 2 2 1 9
13 Glivec (DFSP) 0 2 2 0 1 2 1 1 9
14 Torisel 1 0 2 2 2 0 1 1 9
15 Ventavis 2 0 1 1 2 0 1 1 8
16 Zavesca 1 1 2 1 0 0 1 2 8
17 Tracleer 1 1 1 0 2 0 1 2 8
18 Volibris 2 2 0 1 0 0 1 2 8
19/20 Nexavar (RCC) 1 0 2 0 2 1 2 0 8
  THRESHOLD 50 %         8 points
21 Vidaza 1 0 2 1 0 0 2 1 7
22 Sprycel 1 1 2 0 0 1 1 1 7
23 Revlimid (MM) 1 0 2 1 0 0 2 1 7
24 Atriance 1 0 2 1 0 2 1 0 7
25 Glivec (ALL Ph+) 0 1 2 0 1 0 1 0 5
26 Revatio 0 1 1 0 0 0 1 2 5
27 Glivec (MDS/MPD) 0 0 2 0 1 0 1 0 4
  THRESHOLD 25 %         4 points
  1. Adv.tech. Advancement of technology, Sci. evid. clin.eff. scientific evidence for clinical efficiency, HCC Hepatocellular carcinoma, GIST Malignant gastrointestinal stromal tumors, MM/S Myeloproliferative syndrome, DFSP Dermatofibrosarcoma protuberans, RCC Renal cell carcinoma, MM Multiple myeloma, ALL Ph+ Philadelphia chromosome positive chronic myeloid leukemia, MDS/MPD Myelodysplastic/myeloproliferative diseases